Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab maintenance after radical local therapy for PD-L1-positive high-risk locally advanced oral squamous cell carcinoma
ChiCTR2400089242Phase 2Not yet recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- Sep 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in Oral Mucosal Carcinoma, sponsored by Hunan Cancer Hospital. Primary endpoint: 2-year disease-free survival rate. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
Oral Mucosal Carcinoma
Beyond the preview
Go deeper on ChiCTR2400089242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089242.